Bayer

Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Pharmaceutical Business Review
Adempas
Bayer
PAH
clinical trials
Flag link:
Bayer Agrees To Buy Personalized Vitamin Company Care/of At $225 Million Valuation
Bayer Agrees To Buy Personalized Vitamin Company Care/of At $225 Million Valuation
Forbes
Bayer
M&A
Care/of
consumer health
Flag link:
Triumvira Immunologics raises $55M in Series A funding round for new form of cancer cell therapy
Triumvira Immunologics raises $55M in Series A funding round for new form of cancer cell therapy
MedCity News
Triumvira
Bayer
clinical trials
cell therapy
cancer
Flag link:
Bayer strikes $98m deal with digital health firm One Drop
Bayer strikes $98m deal with digital health firm One Drop
Pharmaforum
Bayer
One Drop
digital health
mobile apps
Flag link:
Bayer settles 90% of Essure claims for $1.6B
Bayer settles 90% of Essure claims for $1.6B
Mass Device
Bayer
devices
Essure
contraceptives
Flag link:
Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market
Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market
Fierce Biotech
Bayer
KaNDy Therapeutics
M&A
Women's Health
menopause
hot flashes
NT-814
Flag link:
FDA approves Lampit for the treatment of Chagas disease in children
FDA approves Lampit for the treatment of Chagas disease in children
Pharmaceutical Business Review
Lampit
antiprotozoals
FDA
Chagas disease
Bayer
Flag link:
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Fierce Pharma
Bayer
earnings
China
pandemic
COVID-19
Eylea
Flag link:
Bayer helps Harvard spinout Vesigen to $28.5M series A
Bayer helps Harvard spinout Vesigen to $28.5M series A
Fierce Biotech
Bayer
Vesigen Therapeutics
Harvard
RNAi
MRNA
CRISPR
Flag link:
Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Beckers Hospital Review
Big Pharma
drug development
antibiotics
innovation
Eli Lilly
Pfizer
Merck
Boehringer Ingelheim
Bayer
CARB-X
Flag link:
Bayer Settles Roundup Lawsuit for Almost $11 Billion
Bayer Settles Roundup Lawsuit for Almost $11 Billion
Motley Fool
Bayer
Roundup
cancer
Flag link:
Big pharma heads towards important readouts
Big pharma heads towards important readouts
EP Vantage
Ozempic
Novo Nordisk
etrolizumab
Roche
Ipatasertib
finerenone
Bayer
filgotinib
Gilead Sciences
Galapagos
Avalglucosidase alfa
Sanofi
Rinvoq
AbbVie
clinical trials
Flag link:
Bayer’s big kidney disease readout approaches
Bayer’s big kidney disease readout approaches
EP Vantage
Bayer
finerenone
kidney disease
clinical trials
diabetes
diabetic kidney disease
Flag link:
Bayer version of COVID-19 antimalarial hopeful may come with quality concerns: report
Bayer version of COVID-19 antimalarial hopeful may come with quality concerns: report
Fierce Pharma
Bayer
hydroxychloroquine
FDA
COVID-19
Flag link:
Merck and Bayer unveil the data behind their CV ‘success,’ underwhelming the industry
Merck and Bayer unveil the data behind their CV ‘success,’ underwhelming the industry
Endpoints
Merck
Bayer
vericiguat
clinical trials
Flag link:
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
Fierce Biotech
ACC
Merck
Bayer
heart failure
vericiguat
clinical trials
Flag link:
Bayer inks up with “small” Indian biotech for new approach at an old target
Bayer inks up with “small” Indian biotech for new approach at an old target
Endpoints
Bayer
Curadev
Takeda
R&D
India
Flag link:
All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them
All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them
Motley Fool
COVID-19
Gilead Sciences
Mylan
Bayer
chloroquine
hydroxychloroquine
Fujifilm
Avigan
Kevzara
Actemra
Regeneron
Sanofi
Roche
Flag link:
Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment
Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment
Motley Fool
Teva Pharmaceutical
Bayer
hydroxychloroquine
COVID-19
Flag link:
Bayer Is Donating Its Malaria Drug That Could Help Coronavirus Patients In The U.S.
Bayer Is Donating Its Malaria Drug That Could Help Coronavirus Patients In The U.S.
Motley Fool
Bayer
COVID-19
malaria
chloroquine
Flag link:

Pages